Clinical Trials Logo

Pulmonary Thromboembolism clinical trials

View clinical trials related to Pulmonary Thromboembolism.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03595891 Completed - Clinical trials for Pulmonary Thromboembolism

The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung

Start date: January 20, 2017
Phase:
Study type: Observational

A study based on a chart review of participants that presented with a sudden blood clot in the lung

NCT ID: NCT02616991 Completed - Clinical trials for Pulmonary Thromboembolism

Computed Tomography CT Venography During Postpartum Venous Thromboembolism

CTVENPOSTPART
Start date: June 4, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether systematically performing computed tomography (CT) venography (i.e a CT acquisition of the pelvis and of the lower limbs, during the venous phase of opacification) in addition to thoracic CT angiography in women with suspected postpartum pulmonary embolism (PE) results in a gain in venous thromboembolism detection rate.

NCT ID: NCT01580085 Completed - Clinical trials for Obstructive Sleep Apnea

Obstructive Sleep Apnea in Pulmonary Embolism

Start date: November 2009
Phase: N/A
Study type: Observational

Obstructive sleep apnea (OSA) is a clinical syndrome characterized by repetitive closure of the airway and frequent awakenings during sleep. Repeated episodes of hypoxia, decrease in intrathoracic pressure, increased venous return and venous stasis, damage to vascular wall may ensue. An increased tendency for coagulation has also been reported in OSA. Venous stasis, vascular endothelial activation and hypercoagulability are also known risk factors for thromboembolism. All of these pathophysiologic changes in OSA may predispose patients for the development of pulmonary embolism (PE) however there is limited data about role of thromboembolic events in OSA.

NCT ID: NCT01513759 Completed - Pulmonary Embolism Clinical Trials

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

SEATTLE II
Start date: June 7, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right ventricle (RV) to left ventricle (LV) diameter within 48 =/- 6 hours in participants with massive or submassive PE.

NCT ID: NCT01206751 Completed - Aortic Dissection Clinical Trials

Multi-detector Computer Tomography Protocol Project: Chest Imaging Technique and Case Presentation

Start date: April 2010
Phase: N/A
Study type: Observational

Multi-detector computer tomography protocol project: Chest imaging technique and case presentation.

NCT ID: NCT00968929 Completed - Pulmonary Embolism Clinical Trials

Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)

RESUPEC
Start date: June 2006
Phase: Phase 4
Study type: Interventional

Recombinant streptokinase (r-SK) is an effective thrombolytic agent developed with gene engineering. Its characteristics of high output and low production cost make it affordable in treating acute myocardial infarction (AMI) in developing countries. It is unclear whether r-SK can be used in patients with pulmonary embolism (PE). The aim of this study was to investigate the efficacy and safety of 1.5 million IU r-SK by 2 hours infusion and 20,000 IU/kg urokinase (UK) by 2 hours infusion in selected PE patients.